RxDoctor Payments Data

Chelsea Clark, MD

Family Medicine · Scottsboro, ALNPI 1124581137

Payments from drug & device makers

$1,723in general payments, 2019–2025

Across 100 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$379
  • AstraZeneca$279
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$251
  • GSK$109
  • Lilly USA, LLC$106
  • Novo Nordisk$79
  • plus $519 from 14 others

What the payments were for

  • Food & beverage$1,723100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,723 in reported general payments places this provider in the 65th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$27,982
Medicare patients
130
Services billed
441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide111$126,719
EliquisApixaban468$95,203
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$61,972
FarxigaDapagliflozin Propanediol113$59,941
JardianceEmpagliflozin214$51,128
XareltoRivaroxaban212$40,027
RybelsusSemaglutide37$35,323
MounjaroTirzepatide28$28,404
TrulicityDulaglutide27$27,794
EntrestoSacubitril/Valsartan80$24,425
MyrbetriqMirabegron151$23,650
NuedextaDextromethorphan Hbr/Quinidine53$20,651
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$19,037
AptiomEslicarbazepine Acetate53$16,865
LinzessLinaclotide53$16,411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$79$162,043148 claims
AstraZenecaFarxiga, Breztri Aerosphere$279$78,978144 claims
GSKTrelegy Ellipta$109$61,97288 claims
Lilly USA, LLCMounjaro, Trulicity$106$56,19855 claims
Johnson & JohnsonXarelto$68$40,027212 claims
AbbVieLinzess, Vraylar$52$28,39780 claims
Astellas Pharma US IncMyrbetriq$27$23,650151 claims
Sumitomo Pharma America, Inc.Gemtesa$18$12,86473 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Scottsboro

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →